17th North American Regional ISSX Meeting (October 16

P43

6-methoxybenzo[d]thiazole-2-carbonitrile: A Highly Selective Luminogenic Substrate for CYP1A2 Induction and Inhibition Assays
James J. Cali, Promega Corporation; Dongping Ma, Promega Corporation; Timothy A. Moeller, Celsis In Vitro Technologies; James Unch, Promega Corporation; Poncho Meisenheimer, Promega Corporation

P44

Changes in Hepatic Cytochrome P450 Expression after Citrobacter rodentium Infection in Cyp4a10- and Cyp4a14-deficient Mice
Beatrice A. Nyagode, Emory University School of Medicine; Edward T. Morgan, Emory University School of Medicine

P45

Characterization of Cyp2b-Knockdown Mouse Reveals Changes in Lipid Metabolism
Basma Damiri, Clemson Univeristy; William Baldwin, Clemson Univeristy

P46

Comparative analyses of in vitro biotransformation in human liver microsomes and MetaSite based in silico predictions for 70 new chemical entities
Mithat Gunduz, Novartis Institutes for Biomedical Research Inc.; Jennifer L. Bushee, Novartis Institutes for Biomedical Research Inc.; Upendra A. Argikar, Novartis Institutes for Biomedical Research Inc.; Giuliano Berellini, Novartis Institutes for Biomedical Research Inc.; Kevin Colizza, Novartis Institutes for Biomedical Research Inc.; Hong Jiang, Novartis Institutes for Biomedical Research Inc.; Michelle Dennehy, Novartis Institutes for Biomedical Research Inc.; Amanda Cirello, Novartis Institutes for Biomedical Research Inc.; Nigel Waters, Novartis Institutes for Biomedical Research Inc.; Amin Kamel, Novartis Institutes for Biomedical Research Inc.; Franco Lombardo, Novartis Institutes for Biomedical Research Inc.; Shawn Harriman, Novartis Institutes for Biomedical Research Inc.

P47

Comparison of P450 2D and 3A-dependent drug oxidation activities in cynomolgus monkeys, microminipigs, and humans
Hiroshi Yamazaki, Showa Pharmaceutical Univ; Chie Emoto, Showa Pharmaceutical Univ; Ryo Koizumi, Showa Pharmaceutical Univ; Makiko Shimizu, Showa Pharmaceutical Univ; Norie Murayama, Showa Pharmaceutical Univ; Kazuhide Iwasaki, Shin Nippon Biomedical Laboratories; Masahiro Utoh, Shin Nippon Biomedical Laboratories; Yasuhiro Uno, Shin Nippon Biomedical Laboratories

P48

Drug interactions of thalidomide with midazolam in human hepatoma cell line system with differentiated HepaRG cryopreserved
Norie Murayama, Showa Pharmaceutical Univ; Kanako Yajima, Showa Pharmaceutical Univ; Makiko Shimizu, Showa Pharmaceutical Univ; Masahiro Utoh, Showa Pharmaceutical Univ; Hiroshi Yamazaki, Showa Pharmaceutical Univ

P49

Effect of 6 Schisandrins from Wuzhi tablet (Schisandra sphenanthera extract) on the activity of cytochrome P450 3A and p-glycoprotein in rats
Bi Huichang, Sun Yat-sen University; Qin Xiaoling, Sun Yat-sen University; Xue Xinping, Sun Yat-sen University; Wang Ying, Sun Yat-sen University; Chen Xiao, Sun Yat-sen University; Huang Min, Sun Yat-sen University

P50

Effects of CYP2C9*3, *28 and *30 on CYP2C9 Inhibition Profiles and Glyburide Metabolism in Vitro
Keiko Maekawa, National Institute of Health Sciences; Noriko Harakawa, National Institute of Health Sciences; Su-Ryang Kim, National Institute of Health Sciences; Jun-ichi Sawada, National Institute of Health Sciences; Yoshiro Saito, National Institute of Health Sciences

P51

Evaluation of broad-spectrum, irreversible CYP450 inhibitors and an inhibition cocktail for metabolite identification studies
Jennifer L. Bushee, Novartis Institutes for Biomedical Research Inc.; Mithat Gunduz, Novartis Institutes for Biomedical Research Inc.; Kevin Colizza, Novartis Institutes for Biomedical Research Inc.; Amin Kamel, Novartis Institutes for Biomedical Research Inc.; Shawn Harriman, Novartis Institutes for Biomedical Research Inc.; Upendra A. Argikar, Novartis Institutes for Biomedical Research Inc.

P52

Human CYP3A4 Mediates the Biotransformation of Sorafenib to its Major Oxidized Metabolites
Michael Murray, The University of Sydney; Sussan Ghassabian, The University of Sydney; Fanfan Zhou, The University of Sydney; Bruce N. Tattam, The University of Sydney; Munikumar R. Doddareddy, The University of Sydney; David E. Hibbs, The University of Sydney; Tristan Rawling, The University of Sydney

P53

Human Cytochrome P450 2E1 Inhibits Cytochrome P450 2B4's activity by Competing for Cytochrome P450 Reductase through a Synergistic Interaction
Cesar Kenaan, University of Michigan; Erin V Shea, University of Michigan; Hsia-lien Lin, University of Michigan; Haoming Zhang, University of Michigan; Matthew Pratt-Hyatt, University of Michigan; Paul F. Hollenberg, University of Michigan

P55

Identification of Cytochrome P450 Enzymes Involved in Microsomal Metabolism of 20(S)-Protopanaxadiol in Human Liver and Intestine
Nga Ting Colette Chiu, University of British Columbia; Subrata Deb, Vancouver Prostate Centre; Hans Adomat, Vancouver Prostate Centre; William Jia, University of British Columbia; Emma Guns, Vancouver Prostate Centre

P56

In Vitro Assessment of Methylene Blue Hydrate as a Multiple CYP450 Inhibitor and a Mechanism-Based Inhibitor
HyunJi Jeong, SK Biopharmaceuticals; Yeonjung Choi, SK Biopharmaceuticals; Myoungki Baek, SK Biopharmaceuticals; Hongsik Moon, SK Biopharmaceuticals

P57

In vitro metabolism of corydaline and characterization of cytochrome P450 enzymes responsible for its metabolism in human liver microsomes
Hye Young Ji, The Catholic University of Korea; Sae Rom Lim, The Catholic University of Korea; Hye Ri Lee, The Catholic University of Korea; Hye Suk Lee, The Catholic University of Korea

P58

Inhibitory Properties of Trapping Agents, Reducing Agents, Radical Scavengers or Chemical Inhibitors Against Major Human Cytochrome P450 Isoforms
Jasleen Sodhi, Genentech Inc.; Erlie Delarosa, Genentech Inc.; Patrick M. Dansette, Uninersit� Paris Descartes; Cyrus Khojasteh, Genentech Inc.

P59

MECHANISM-BASED INACTIVATION OF CYTOCHROME P450 2B6 BY METHADONE
Hemali Amunugama, University of Michigan

P60

METABOLISM AND METABOLIC ACTIVATION OF FOOD-COMPOSITION BY HUMAN P450 VARIANTS REPRESENTING SINGLE NUCLEOTIDE POLYMORPHISMS
Hiromasa Imaishi, Kobe University; Tatsushi Goto, Kobe University; Taiki Mori, Kobe University; Mai Hatta, Kobe University; Maki Matui, Kobe University; Takashi Hikawa, Kobe University

P61

Milk thistle extracts and components differentially modulate hepatic CYP1A2, CYP2C19, and CYP2D6 activity
Vanessa Gonz�lez-P�rez, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill; Scott J. Brantley, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill; Tyler N. Graf, The University of North Carolina at Greensboro; David J. Kroll, North Carolina Central University; Nicholas H. Oberlies, The University of North Carolina at Greensboro; Mary F. Paine, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill

P62

Modification of Cytochrome P450 3A4 by Soft Electrophiles Leads to Differential Residual Activity
Dan A. Rock, Amgen Inc; John A. Davis, Amgen Inc.; Brooke M. VandenBrink, Amgen Inc

P63

NNK-induced malignant transformation in human breast epithelial cells expressing CYP2A13
Jun-Yan Hong, University of Medicine and Dentistry of New Jersey; Ding Ding, Zhejiang University; Yu Guo, Wuhan University; Shuqing Chen, Zhejiang University

P64

Novel Catalytic Properties and Physiologic Functions of Cytochrome P450 from Streptomyces coelicolor
Qian Cheng, Vanderbilt University; Fred & Peter Guengerich, Vanderbilt University

P65

Predicting Oxidation Sites with Order of Occurrence among Multiple Sites for CYP4A-Mediated Reactions
Yoshiyuki Yamaura, Ono Pharmaceutical Co., Ltd.; Kouichi Yoshinari, Tohoku University; Yasushi Yamazoe, Tohoku University

P66

Predicting Regioselectivity and Lability of Cytochrome P450 Metabolism using Quantum Mechanical Simulations
Matthew D. Segall, Optibrium Ltd.

P67

Protein Binding, Transmembrane Transport and Enzyme Interactions on the Processing of Schisandrin in Rat Liver
Jing-jing Wu, Dalian Institute of Chemical Physics, Chinese Academy of Sciences; Yan-yan Zhang, Dalian Institute of Chemical Physics, Chinese Academy of Sciences; Chun-zhi Ai, Dalian Institute of Chemical Physics, Chinese Academy of Sciences; Ling Yang, Dalian Institute of Chemical Physics, Chinese Academy of Sciences

P68

Single Nucleotide Polymorphisms in Prostaglandin I2 Synthase Gene (CYP8A1) in a Korean Population and their Comparative Analysis with other Ethnic Groups
Sun-Ah Cho, Inje University College of Medicine; Woo-Young Kim, Inje University College of Medicine; Sang Seop Lee, Inje University College of Medicine; Jae-Gook Shin, Inje University College of Medicine; Su-Jun Lee, Inje University College of Medicine

P69

Stable Transfection of CYP2D6 Gene into HepaRG Cells
Lai Peng, University of Kansas Medical Center; Steven N. Hart, University of Kansas Medical Center; Xiao-bo Zhong, University of Kansas Medical Center

P70

Structural Features of Midazolam Allostery by Cytochrome P450 3A4
Arthur G. Roberts, University of Georgia

P72

The biomonitoring of naphthols in urine and some oxidative stress parameters in workers exposed to jet fuel (JP-8)
Ahmet Sayal, Gulhane Military Medical Academy; Onur Erdem, Gulhane Military Medical Academy; Ay�e Eken, Gulhane Military Medical Academy; Cemal Akay, Gulhane Military Medical Academy; Ahmet Aydin, Yeditepe University, Faculty of Pharmacy

P73

The effect of aluminium on testese and antioxidant system in rats
Cemal Akay, Gulhane Military Medical Academy; Onur Erdem, Gulhane Military Medical Academy; Ahmet Aydin, Yeditepe University; Ayse Eken, Gulhane Military Medical Academy; Ahmet Sayal, Gulhane Military Medical Academy